Apremilast and Adalimumab in Psoriatic Arthritis Patients
Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-70
SponsorTanta University
About this trial
The aim of this work is to compare the efficacy of Apremilast combined with Methotrexate versus Adalimumab combined with Methotrexate
Eligibility criteria
Qualifiers
This study will include 60 adult Psoriatic arthritis patients >18 years old, fulfilling the (CASPAR) classification criteria of Psoriatic arthritis and have an inadequate response to methotrexate therapy for at least 3 months.
Psoriatic arthritis patients with peripheral musculoskeletal domains (peripheral arthritis, dactylitis and enthesitis) as well as skin and nail domains
Disqualifiers
Patients who received previous biologic agents or Janus kinase inhibitors.
Patients with axial and ocular involvement.
Current or recent serious infection including tuberculosis or hepatitis B/C .
Current or past history of malignancy (within five year).
Trial design
Treatments tested in this trial
- Adalimumab
- Apremilast
Treatment groups
60 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov